Furthermore, by examining the “inactive” pseudokinase ErbB3 and characterizing its weak activity, we justify an alternate means of resistance to ErbB TKI inhibition and propose that targeting of ErbB3 may represent a superior therapeutic strategy for certain ErbB-driven cancers. This evidence concerns the gene EGFR and cancer.